ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,284.91
0.20%
Dow Jones
42,216.27
0.72%
Gold vs US Dollar
2,671.165
0.52%
Brent Oil
70.955
-3.05%
Bitcoin
65,238.06
3.34%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) News

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KALV
DateTimeSourceHeadlineSymbolCompany
26/09/202411:30Business WireKalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)NASDAQ:KALVKalVista Pharmaceuticals Inc
11/09/202421:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
11/09/202421:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
11/09/202401:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202421:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202412:00Business WireKalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202411:30Business WireKalVista Appoints Brian Piekos as Chief Financial OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/09/202411:30Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
05/09/202421:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
05/09/202421:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
05/09/202411:30Business WireKalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
04/09/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
03/09/202411:30Business WireKalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
29/08/202411:30Business WireKalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin SymposiumNASDAQ:KALVKalVista Pharmaceuticals Inc
27/08/202401:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
27/08/202400:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202421:17Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202421:13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202421:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202402:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202402:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202402:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
15/08/202411:30Business WireKalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
02/08/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
23/07/202421:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
22/07/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KALVKalVista Pharmaceuticals Inc
16/07/202421:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
11/07/202421:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
11/07/202421:49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KALVKalVista Pharmaceuticals Inc
11/07/202421:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KALVKalVista Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:KALV

Your Recent History

BIT
P1XD83
NLBNPIT1XD83 20991231 15...
AMEX
SMOG
VanEck Low Carbon Energy...
NYSE
VNE
Veoneer
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved